Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AbbVie Inc | London | Healthcare | Pharmaceuticals | £241.01B | 78x | -2.9 | GBX 15,561.65 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk L | London | Healthcare | Pharmaceuticals | £226B | 19.5x | 1.05 | GBX 5,142.65 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding Participation | London | Healthcare | Pharmaceuticals | £187.45B | 26.7x | -0.89 | GBX 23,445.08 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding | London | Healthcare | Pharmaceuticals | £187.45B | 26.7x | -0.9 | GBX 24,795.02 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbott Laboratories L | London | Healthcare | Healthcare Equipment & Supplies | £170.59B | 17.1x | 0.12 | GBX 9,888.31 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis | London | Healthcare | Pharmaceuticals | £163.14B | 17.5x | -1.3 | GBX 8,387.61 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | London | Healthcare | Pharmaceuticals | £161.55B | 28.1x | 1.24 | GBX 10,416 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.7% Upside | Upgrade to Pro+ | |
Merck & Co Inc | London | Healthcare | Pharmaceuticals | £142.06B | 11.1x | 0.02 | GBX 5,618.68 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | London | Healthcare | Pharmaceuticals | £100.18B | 22.6x | 0.02 | GBX 8,010.12 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Essilor International | London | Healthcare | Healthcare Equipment & Supplies | £94.90B | 47.9x | 49.31 | GBX 20,772.05 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi L | London | Healthcare | Pharmaceuticals | £93.94B | 18.5x | 0.46 | GBX 7,706.35 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | London | Healthcare | Pharmaceuticals | £58.59B | 18.8x | -0.61 | GBX 1,443.50 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.8% Upside | Upgrade to Pro+ | |
Siemens Healthineers | London | Healthcare | Healthcare Equipment & Supplies | £44.12B | 26.4x | 1.74 | GBX 3,948.70 | -17.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck KGaA | London | Healthcare | Pharmaceuticals | £42.15B | 17.8x | 5.09 | GBX 9,694.74 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HALEON | London | Healthcare | Pharmaceuticals | £37.38B | 25x | 0.66 | GBX 416.20 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2.7% Upside | Upgrade to Pro+ | |
Lonza Group | London | Healthcare | Biotechnology & Medical Research | £35.59B | 58x | GBX 50,338.23 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
IDEXX Laboratories | London | Healthcare | Healthcare Equipment & Supplies | £30.72B | 47.2x | 9.4 | GBX 38,229 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
arGEN X BV | London | Healthcare | Biotechnology & Medical Research | £26.01B | 32.6x | 0.09 | GBX 42,599.88 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
UCB L | London | Healthcare | Pharmaceuticals | £24.84B | 27.9x | 0.13 | GBX 13,067.37 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Humana | London | Healthcare | Healthcare Providers & Services | £20.42B | 16.1x | -1.3 | GBX 17,075.26 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bayer L | London | Healthcare | Pharmaceuticals | £20.39B | -7.5x | 1.6 | GBX 2,075.53 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Fresenius SE Co KGaA | London | Healthcare | Healthcare Providers & Services | £20.01B | 20x | 0.12 | GBX 3,555.30 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Coloplast AS | London | Healthcare | Healthcare Equipment & Supplies | £16.09B | 31.6x | -3.11 | GBX 7,212.84 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Koninklijke Philips | London | Healthcare | Healthcare Equipment & Supplies | £15.77B | 78.4x | 0.53 | GBX 1,704.33 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sandoz | London | Healthcare | Pharmaceuticals | £15.62B | GBX 3,647.41 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Biogen | London | Healthcare | Pharmaceuticals | £13.88B | 12.6x | 0.47 | GBX 9,642.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sonova Holding | London | Healthcare | Healthcare Equipment & Supplies | £13.79B | 28.3x | -2.85 | GBX 23,116.66 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Fresenius Medical Care | London | Healthcare | Healthcare Providers & Services | £12.48B | 24.1x | 0.87 | GBX 4,243.23 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cooper Companies | London | Healthcare | Healthcare Equipment & Supplies | £11.90B | 38.5x | 0.91 | GBX 5,972.05 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Align Tech | London | Healthcare | Healthcare Equipment & Supplies | £9.70B | 32.8x | -3.24 | GBX 13,385.68 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab | London | Healthcare | Biotechnology & Medical Research | £9.55B | 11.5x | 0.12 | GBX 15,615.06 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Smith & Nephew | London | Healthcare | Healthcare Equipment & Supplies | £9.40B | 30.8x | 0.54 | GBX 1,075 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.7% Upside | Upgrade to Pro+ | |
Eurofins Scientific SE FRA | London | Healthcare | Biotechnology & Medical Research | £9.20B | 30.8x | 0.69 | GBX 4,771.12 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Recordati Industria | London | Healthcare | Pharmaceuticals | £8.95B | 25.5x | 3.33 | GBX 4,350.99 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Swedish Orphan Biovitrum publ | London | Healthcare | Pharmaceuticals | £7.76B | 25.5x | 0.32 | GBX 2,282.08 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | London | Healthcare | Biotechnology & Medical Research | £7.17B | 104.1x | -1.33 | GBX 3,312.30 | -9.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ipsen L | London | Healthcare | Pharmaceuticals | £7.11B | 23.9x | -0.51 | GBX 8,613.82 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Orion Oyj | London | Healthcare | Pharmaceuticals | £6.84B | 23.4x | 0.39 | GBX 4,894.87 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
William Demant | London | Healthcare | Healthcare Equipment & Supplies | £6.15B | 19.4x | 0.52 | GBX 2,939.11 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ConvaTec Group | London | Healthcare | Healthcare Equipment & Supplies | £5.90B | 43x | 0.87 | GBX 289.20 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.9% Upside | Upgrade to Pro+ | |
Grifols Pref | London | Healthcare | Pharmaceuticals | £5.47B | 33.1x | GBX 618.39 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Grifols | London | Healthcare | Pharmaceuticals | £5.47B | 33.1x | GBX 804.40 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Hikma Pharma | London | Healthcare | Pharmaceuticals | £4.70B | 17.7x | 0.19 | GBX 2,132 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.8% Upside | Upgrade to Pro+ | |
Sectra AB | London | Healthcare | Healthcare Equipment & Supplies | £4.61B | 101.8x | 2.62 | GBX 2,412.48 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ALK-ABELLO | London | Healthcare | Pharmaceuticals | £4.42B | 42.4x | 0.57 | GBX 1,680.41 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Carl Zeiss Meditec | London | Healthcare | Healthcare Equipment & Supplies | £4.27B | 32.9x | -0.81 | GBX 4,885.08 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
DiaSorin | London | Healthcare | Healthcare Equipment & Supplies | £4.13B | 25.5x | GBX 7,666.97 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Richter Gedeon Vegyeszeti Gyar | London | Healthcare | Pharmaceuticals | £3.95B | 8x | 0.14 | GBX 1,048.10 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Getinge AB | London | Healthcare | Healthcare Equipment & Supplies | £3.93B | 34.5x | -0.96 | GBX 1,445.24 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
H Lundbeck L | London | Healthcare | Pharmaceuticals | £3.91B | 11.2x | 0.3 | GBX 409.02 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |